reticulocyte hemoglobin content
Recently Published Documents


TOTAL DOCUMENTS

76
(FIVE YEARS 19)

H-INDEX

14
(FIVE YEARS 2)

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S12-S13
Author(s):  
Nicholas E Larkey ◽  
Christopher L Rosemark ◽  
Darci R Block

Abstract Reticulocyte hemoglobin content (Ret-He, the hemoglobin within reticulocytes or immature red blood cells) and immature reticulocyte fraction (IRF, the immature fraction of the absolute-reticulocyte-count) are tests that provide insight into erythropoiesis and iron status earlier than conventional iron studies offering the added benefit of not being acute-phase-reactants. Studies have shown that Ret-He is a diagnostic marker for iron-deficiency-anemia (IDA), but fewer studies have investigated IRF. Our laboratory is currently planning to report these parameters when reticulocyte is ordered. Since these are new parameters, we wanted to investigate their overall correlation with complete blood count (CBC) and other iron studies to gain a better appreciation of their utility in our patient population. The aim of this study was to compare the overall correlation of Ret-He and IRF with seven tests used in the evaluation of IDA. To our knowledge these parameters have not all been directly correlated within a single study. CBC and reticulocytes were quantified using XN 9000 hematology analyzers (Sysmex Corporation), ferritin (DXI 800, Beckman Coulter Inc.), and % iron-saturation (measured using total iron-binding-capacity (TIBC)=transferrin*1.18 on Cobas 6000, Roche Diagnostics). Two de-identified cohorts of patients undergoing physician-ordered reticulocyte testing were used for this analysis. Dataset 1 (DS1): (N=2026 from Mayo Clinic Florida) had Ret-He and IRF compared to absolute-reticulocyte-count (Ret), ferritin and % iron saturation. Dataset 2 (DS2): (N=3990 from Mayo Clinic Rochester) had Ret-He and IRF compared to the red-cell-indices of the CBC including hemoglobin (Hgb), mean-corpuscular-volume (MCV), mean-corpuscular-hemoglobin (MCH), and mean-corpuscular-hemoglobin-concentration (MCHC). Correlation coefficients were calculated using Spearman rank-order (ρ) wherein values below +/-0.39 are weak, between +/-0.40-0.59 are considered moderate, and values above +/-0.60 are considered strong. For DS1, Ret-He demonstrated the following correlations: Ret (ρ=0.01), ferritin (ρ=0.33), % iron saturation (ρ=0.63). IRF demonstrated: Ret (ρ=0.46), ferritin (ρ=-0.05), % iron saturation (ρ=-0.22). For DS2, Ret-He demonstrated the following correlations: Hgb (ρ=0.17), MCV (ρ=0.64), MCH (ρ=0.74), MCHC (ρ=0.56). IRF demonstrated Hgb (ρ=-0.41), MCV (ρ=0.10), MCH (ρ=0.04), MCHC (ρ=-0.11). Ret-He and IRF demonstrated different correlative profiles suggesting they may have differing uses. Ret-He was strongly positively-correlated with % iron saturation, MCV, MCH and moderately positively-correlated with MCHC. These positive-correlations are consistent with relationships established in the literature. Interestingly, Ret-He was only weakly correlated with ferritin, possibly owing to ferritin being an acute-phase-reactant. IRF had a moderate positive correlation with Ret and moderate inverse correlation with Hgb. Both of these IRF relationships are consistent with other reports, but both relationships have not been shown in the same study before, preventing direct comparison until now. The literature suggests IRF may have more potential in monitoring treatment than in diagnosis. One limitation of these datasets is their lack of clinical correlation such as established iron-deficiency, anemia status, or treatment information.


2021 ◽  
Vol 14 (3) ◽  
pp. 1359-1362
Author(s):  
Zahraa Jasim ◽  
Hayder Aledan

Background and objective: Iron deficiency is a well-documented cause of diffuse non-scarring hair loss. We aimed to find the best representative laboratory parameter for iron deficiency. Methods:This was a cross-sectional observational study conducted on 51 female patients with diffuse non-scarring hair loss and iron deficiency state. Iron deficiency was diagnosed as serum ferritin below 30 ng/ml, TSAT below 20% or CHr below 29 pg. Results: Among 51 female patients with diffuse non-scarring hair loss with laboratory proven iron deficiency; low CHrwas reported in 50 (98%) patients, low TSAT was reported in 43 (84.3%) patients, low serum ferritin was reported in 28 (55%). Conclusion:The reticulocyte hemoglobin content (CHr) shows the highest frequency of iron deficiency in patients with diffuse hair loss and iron deficiency state.


2020 ◽  
Vol 49 (4) ◽  
pp. 557-566
Author(s):  
Miriam Keiner ◽  
Jannika Fuchs ◽  
Natali Bauer ◽  
Andreas Moritz

Author(s):  
Timothy M. Bahr ◽  
Vickie L. Baer ◽  
Robin K. Ohls ◽  
Thomas R. Christensen ◽  
Diane M. Ward ◽  
...  

2020 ◽  
Vol 21 (19) ◽  
pp. 7153
Author(s):  
Chie Ogawa ◽  
Ken Tsuchiya ◽  
Naohisa Tomosugi ◽  
Kunimi Maeda

Roxadustat (Rox), a hypoxia-inducible factor (HIF) stabilizer, is now available for the treatment of anemia in hemodialysis (HD) patients. To investigate hematopoietic effect and iron metabolism, this study involved 30 HD patients who were initially treated with darbepoetin (DA), a conventional erythropoietin-stimulating agent, and then switched to Rox. We measured erythrocyte, reticulocyte indices, and iron-related factors at every HD during the first two weeks after the treatment switch (Days 0–14) and again on Days 21 and 28. We measured erythropoietin (EPO) concentration every week and examined their changes from Day-0 values. The same variables were measured in 15 HD patients who continued DA at every HD for one week. Iron-related factors were also measured on Days 14 and 28. In the Rox group, hepcidin significantly decreased from Day 2. The reticulocyte hemoglobin content (CHr) significantly increased on Day 4, but decreased with a significant increase in reticulocyte count from Day 7. Log10(serum ferritin) significantly decreased after Day 11. Log10(EPO concentration) was lower at all time points. Compared with the DA group, the Rox group showed significant differences in all variables except CHr. These results suggest that Rox improves hematopoiesis and iron metabolism early after administration independent of EPO concentration.


2020 ◽  
Vol 42 (4) ◽  
Author(s):  
Thamires Aparecida Dzirba ◽  
Mariane de Faria Moss ◽  
Laura Mattana Dionisio

2020 ◽  
Vol 504 ◽  
pp. 138-145 ◽  
Author(s):  
Chie Ogawa ◽  
Ken Tsuchiya ◽  
Kunimi Maeda

Sign in / Sign up

Export Citation Format

Share Document